Xiaoxian (Bill) Li, MD, PhD, is Professor and serves as Director of Breast Pathology and Director of Immunohistochemistry Laboratory in the Department of Pathology and Laboratory Medicine of Emory University School of Medicine. Board certified in clinical and anatomic pathology, Dr. Li specializes in breast pathology.
Dr. Li is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University. He serves as co-chair of the Faculty Affair Committee for the Emory University School of Medicine Asian Americans and Pacific Islanders affinity group. At the national level, he currently serves in multiple national committees for various organizations including College of American Pathologists, United States and Canadian Academy of Pathology, Food and Drug Administration and I-SPY Trial Pathology Working Group.
Dr. Li is a standing member of an American Cancer Society Grant Review Committee, and an ad hoc grant reviewer for National Institutes of Health, National Cancer Institute, Department of Defense, American Cancer Society grants and Breast Cancer Now, England.
Dr. Li has mentored numerous PhD and Master's students, residents, fellows and visiting scholars and has been frequently invited to give lectures at national/international conferences including the United States and Canadian Academy of Pathology and College of American Pathologists annual meetings.
Dr. Li received his Medical Degree from Beijing Medical University in Beijing, China. He obtained his PhD from The University of Maryland in College Park, Maryland. He completed his postdoctoral training as a Postdoctoral Associate in the Department of Pharmacology at Fox Chase Cancer Center in Philadelphia, Pennsylvania and then as a Research Associate in the Breast Center at Baylor College of Medicine in Houston, Texas. He completed his anatomic pathology/clinical pathology residency training at The Methodist Hospital in Houston and an oncological pathology fellowship and a breast pathology fellowship at UT MD Anderson Cancer Center in Houston, Texas.
Dr. Li's research interests focus on all aspects of breast diseases from benign to malignant neoplasms, particularly developing predictive markers in breast cancer and studying the mechanisms underlying tumor initiation, progression and metastasis.
Dr. Li has published numerous peer reviewed publications, review articles and book chapters. Two of his first authored and co-first authored papers on breast cancer stem cells (PMID: 18445819; 19666588) have been cited more than 1,000 times respectively per Web of Science.
Dr. Li serves as Section Editor of Breast Pathology for Archives of Pathology and Laboratory Medicine, the official journal of CAP. He also serves on the editorial board of Breast Cancer Research and Treatment, Clinical Breast Cancer and Human Pathology.
#3 the most cited papers in Clinical Breast Cancer since 2018 (PMID: 30846407), 2022
Emory Millipub Club Award, Emory University School of Medicine, 2018, 2022
Award for Outstanding Contributions to Clinical Science Research, Department of Pathology and Laboratory Medicine, Emory University, 2019
Fellow Research Award ($10,000), Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center, 2012-2013
Poster Presentation Competition 2rd Place, 89th Texas Society of Pathologists Annual Meeting, Galveston, TX, 2010
Poster Presentation Competition 3rd Place, 88th Texas Society of Pathologists Annual Meeting, Austin, TX, 2009
Podium Presentation Competition 2nd Place, 87th Texas Society of Pathologists Annual Meeting, Houston, TX, 2008
Department of Defense Breast Cancer Training Grant, Fox Chase Cancer Center, 2002-2004
Eugenie Clark Summer Research Fellowship, University of Maryland, 2001
College of Life Sciences Travel Award, University of Maryland, 2000 & 2001
Jacob K. Goldhabor Travel Award, University of Maryland, 2000
Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
